BioLife Solutions, Inc. Aktie News

BOTHELL, Wash. , Oct. 23, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025.

BOTHELL, Wash. , Oct. 7, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools for the cell and gene therapy ("CGT") market, announces the sale of SAVSU Cleo Technologies, LLC.

After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses which it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing.

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Roderick de Greef - CEO & Chairman Troy Wichterman - Chief Financial Officer Conference Call Participants Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division Chad M. Wiatrowski - TD Cowen, Research Division Matthew Jay Stanton - Jefferies LLC, Research Division Yi...

Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62%  and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue Raises full-year 2025 revenue guidance to $100.0 million - $103.0 million, and full-year 2025 Cell Processing revenue g...

BOTHELL, Wash. , July 28, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced that as part of a larger round of financing it has purchased $2 million of convertible notes in Pluristyx, Inc. ("Pluristyx"), a Seattle based developer of innovative induced p...

BOTHELL, Wash. , July 24, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025.

BOTHELL, Wash. , May 14, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the company will be participating in the following investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference May 28, 2025 Minneapolis, MN at the Renaissan...